Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.31 |
| ▸ | RGS12 | O14924 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24627389 | 0.83 | EPHX2 (0.38) | EPHX2DPP4DPP7MAPK8CD38 | |
| SCHEMBL22996544 | 0.80 | EPHX2 (0.38) | EPHX2DPP4DPP7ATMCD38 | |
| SCHEMBL21452828 | 0.80 | ATM (0.50) | EPHX2ATM | |
| SCHEMBL20242212 | 0.80 | EPHX2 (0.38) | EPHX2DPP4DPP7ATMCD38 | |
| SCHEMBL22996466 | 0.80 | ATM (0.50) | EPHX2ATM | |
| SCHEMBL20654282 | 0.80 | ATM (0.50) | EPHX2ATM | |
| SCHEMBL24198568 | 0.78 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL22633559 | 0.78 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL22395802 | 0.78 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL22633560 | 0.78 | EPHX2 (0.30) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152018-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-20220242852-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242852-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | EPHX2 1579/4885DPP4 2699/4885DPP7 1575/4885 |
| US-12152018-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | EPHX2 1284/4885DPP4 3242/4885DPP7 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.